Although a further hypoalbuminuric effect has been noted after adding SDX therapy to ACEI in a subgroup in DiNAS [23], as well as another GAG, enoxaparin cannot counter the renal hemodynamic changes including an increase in mean arterial pressure and a decrease in renal plasma flow post angiotensin II (AngII) infusion in DKD patients [30], suggesting the SDX activity is partially independent of the ACEI/ARB effects; whether SDX and ACEI/ARB have totally different pharmacological targets on hypoalbuminuria remains unclear. Here, AGT is linked to diabetic kidney disease.